Clinical Trial Update: DP-R212 Pharmacokinetic Study [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of DP-R212 sponsored by Alvogen Korea. It targets hypertension and hyperlipidemia; current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Hypertension

Drugs mentioned

• DP-R212

Snippet

Sponsor: Alvogen Korea | Conditions: Hypertension, Hyperlipidemias | Phase 1 | Status: UNKNOWN